Literature DB >> 16945006

Human tissue for in vitro research as an alternative to animal experiments: a charitable "honest broker" model to fulfil ethical and legal regulations and to protect research participants.

Wolfgang E Thasler1, Thilo Schlott, Arno Kalkuhl, Thomas Plän, Bernhard Irrgang, Karl-Walter Jauch, Thomas S Weiss.   

Abstract

Research with human tissue offers the possibility not only of improving preclinical pharmaceutical research and safety assessment, but also of the substitution of some animal experiments. Surgically removed human tissue is discarded after pathological evaluation. This tissue would be of enormous value for research, especially in the pharmaceutical branch, if it were readily available in an ethically and legally approved manner. But there are public concerns about the use of human tissue, especially for "commercial" purposes, such as in the pharmaceutical industry. The question is whether the ethical boundaries are sufficiently respected in the course of striving for industrial profit. To overcome this problem, a clear procedure for tissue donation, collection, supply and allocation must be established, which is guaranteed to be independent of special interests. The persisting problem seems to be the lack of an authority which asks for informed consent, coordinates tissue as well as blinded data collection, and supplies research facilities with tissue samples in a transparent manner. Therefore, a charitable, state-controlled foundation acting as an "honest broker" was initiated, to cover the ethical and legal aspects, as well as to protect the research participants in their use of human tissue as an alternative to animal experiments.

Entities:  

Mesh:

Year:  2006        PMID: 16945006     DOI: 10.1177/026119290603400411

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  7 in total

Review 1.  Biobanking for research in surgery: are surgeons in charge for advancing translational research or mere assistants in biomaterial and data preservation?

Authors:  Wolfgang E Thasler; Reinhard M K Thasler; Celine Schelcher; Karl-Walter Jauch
Journal:  Langenbecks Arch Surg       Date:  2013-02-22       Impact factor: 3.445

2.  Scientists' perspectives on consent in the context of biobanking research.

Authors:  Zubin Master; Lisa Campo-Engelstein; Timothy Caulfield
Journal:  Eur J Hum Genet       Date:  2014-07-30       Impact factor: 4.246

3.  A multidisciplinary approach to honest broker services for tissue banks and clinical data: a pragmatic and practical model.

Authors:  Rajiv Dhir; Ashok A Patel; Sharon Winters; Michelle Bisceglia; Dennis Swanson; Roger Aamodt; Michael J Becich
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

4.  Incorporating exclusion clauses into informed consent for biobanking.

Authors:  Zubin Master; David B Resnik
Journal:  Camb Q Healthc Ethics       Date:  2013-04       Impact factor: 1.284

5.  Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells.

Authors:  Sascha Venturelli; Alexander Berger; Alexander Böcker; Christian Busch; Timo Weiland; Seema Noor; Christian Leischner; Sabine Schleicher; Mascha Mayer; Thomas S Weiss; Stephan C Bischoff; Ulrich M Lauer; Michael Bitzer
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

Review 6.  Stem cell preservation for regenerative therapies: ethical and governance considerations for the health care sector.

Authors:  Zubin Master; Aidan P Crowley; Cambray Smith; Dennis Wigle; Andre Terzic; Richard R Sharp
Journal:  NPJ Regen Med       Date:  2020-12-01

7.  Preclinical Efficacy and Toxicity Analysis of the Pan-Histone Deacetylase Inhibitor Gossypol for the Therapy of Colorectal Cancer or Hepatocellular Carcinoma.

Authors:  Mascha Mayer; Alexander Berger; Christian Leischner; Olga Renner; Markus Burkard; Alexander Böcker; Seema Noor; Timo Weiland; Thomas S Weiss; Christian Busch; Ulrich M Lauer; Stephan C Bischoff; Sascha Venturelli
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.